A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia

Trial Profile

A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 06 Dec 2016 Results (n=13) of this and two other studies assessing mutational mechanism of Idelaliisb presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Jun 2016 Results of post-hoc analysis of this and other trials (n=1073) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results (n=283) of post-hoc pooled analysis of this and other trials ( NCT01539512 and NCT01659021) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top